The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
Open accessAbstract
Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P<0.0001). Adenosquamous and squamous carcinomas of the lung had a lower percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and 17.3% of tumours being Ep-CAM negative. With the exception of moderately differentiated colon carcinoma, where patients not expressing Ep-CAM on their tumours showed an inferior survival (P=0.0014), correlation of Ep-CAM expression with survival did not reach statistical significance for any of the other cancer indications and subgroups. In conclusion, the data strongly support the notion that Ep-CAM is a prime target for immunotherapies in major human malignancies. This is because the most common human cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent EpCam protein expression in human carcinomas
Went, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., & Dirnhofer, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.026 · Cited by 819
Self-citationColorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.
Herlyn, M., Steplewski, Z., Herlyn, D., & Koprowski, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1438 · Cited by 656
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy
Osta, W. A., Chen, Y., Mikhitarian, K., Mitas, M., Salem, M., Hannun, Y. A., Cole, D. J., & Gillanders, W. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0754 · Cited by 563
Transcriptional regulation of cadherins during development and carcinogenesis
Peinado, H., Portillo, F., & Cano, A. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041794hp · Cited by 561
The biology of the 17–1A antigen (Ep-CAM)
Balzar, M., Winter, M. J., de Boer, C. J., & Litvinov, S. V. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900038 · Cited by 545
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.
Litvinov, S. V., Velders, M. P., Bakker, H. A., Fleuren, G. J., & Warnaar, S. O. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.2.437 · Cited by 524
Bubendorf, L., Nocito, A., Moch, H., & Sauter, G. (2001) · The Journal of Pathology · doi:10.1002/path.893 · Cited by 398
Self-citationThe carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation
Münz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., & Gires, O. (2004) · Oncogene · doi:10.1038/sj.onc.1207610 · Cited by 368
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
Self-citationLitvinov, S. V., Balzar, M., Winter, M. J., Bakker, H. A. M., Bruijn, I. H. B.-D., Prins, F., Fleuren, G. J., & Warnaar, S. O. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.5.1337 · Cited by 310
Ep-CAM overexpression in breast cancer as a predictor of survival
Gastl, G., Spizzo, G., Obrist, P., Dünser, M., & Mikuz, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03312-2 · Cited by 262
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Self-citationHigh Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer
Spizzo, G., Gastl, G., Obrist, P., Went, P., Dirnhofer, S., Bischoff, S., Mirlacher, M., Sauter, G., Simon, R., Stopatschinskaya, S., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000036787.59816.01 · Cited by 254
Self-citationUsing Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Kim, H. L., Seligson, D., Liu, X., Janzen, N., Bui, M. H. T., Yu, H., Shi, T., Figlin, R. A., Horvath, S., & Belldegrun, A. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0488 · Cited by 233
Punt, C. J., Nagy, A., Douillard, J.-Y., Figer, A., Skovsgaard, T., Monson, J., Barone, C., Fountzilas, G., Riess, H., Moylan, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09836-7 · Cited by 213
Winter, M. J., Nagtegaal, I. D., van Krieken, J. H. J. M., & Litvinov, S. V. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63570-5 · Cited by 208
Expression patterns of potential therapeutic targets in prostate cancer
Zellweger, T., Ninck, C., Bloch, M., Mirlacher, M., Koivisto, P. A., Helin, H. J., Mihatsch, M. J., Gasser, T. C., & Bubendorf, L. (2005) · International Journal of Cancer · doi:10.1002/ijc.20615 · Cited by 165
Self-citationPrognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer
Spizzo, G., Obrist, P., Ensinger, C., Theurl, I., Dünser, M., Ramoni, A., Gunsilius, E., Eibl, G., Mikuz, G., & Gastl, G. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10270 · Cited by 152
Varga, M., Obrist, P., Schneeberger, S., Mühlmann, G., Felgel-Farnholz, C., Fong, D., Zitt, M., Brunhuber, T., Schäfer, G., Gastl, G. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0528 · Cited by 145
Prang, N. S., Preithner, S., Brischwein, K., Göster, P., Wöppel, A., Müller, J., Steiger, C., Peters, M. J., Baeuerle, P. A., & da Silva, A. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602310 · Cited by 143
Self-citationEpithelial Cell Adhesion Molecule (KSA) Expression
Seligson, D. B., Pantuck, A. J., Liu, X., Huang, Y., Horvath, S., BUI, M. H. T., Han, K., Correa, A. J., Eeva, M., Tze, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1132-03 · Cited by 138
Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker
Moldenhauer, G., Momburg, F., Möller, P., Schwartz, R., & Hämmerling, G. J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.276 · Cited by 136
Schlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbuese, R., Junghahn, I., Kasimir-Bauer, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2637 · Cited by 132
Self-citationCirulli, V., Crisá, L., Beattie, G. M., Mally, M. I., Lopez, A. D., Fannon, A. M., Ptasznik, A., Inverardi, L., Ricordi, C., Deerinck, T. J., et al. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.6.1519 · Cited by 104
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
Naundorf, S., Preithner, S., Mayer, P., Lippold, S., Wolf, A., Hanakam, F., Fichtner, I., Kufer, P., Raum, T., Riethmüller, G., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10443 · Cited by 100
Self-citationHER‐2 and TOP2A coamplification in urinary bladder cancer
Simon, R., Atefy, R., Wagner, U., Forster, T. H., Fijan, A., Bruderer, J., Wilber, K., Mihatsch, M. J., Gasser, T., & Sauter, G. (2003) · International Journal of Cancer · doi:10.1002/ijc.11477 · Cited by 96
Self-citationIdentification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
Kim, J., Herlyn, D., Wong, K., Park, D. C., Schorge, J. O., Lu, K. H., Skates, S. J., Cramer, D. W., Berkowitz, R. S., & Mok, S. C. (2003) · PubMed · Cited by 89
Identification of genes involved in epithelial-mesenchymal transition and tumor progression
Kiemer, A. K., Takeuchi, K., & Quinlan, M. P. (2001) · Oncogene · doi:10.1038/sj.onc.1204872 · Cited by 77
Hartung, G., Hofheinz, R. D., Dencausse, Y., Sturm, J., Kopp‐Schneider, A., Dietrich, G., Fackler-Schwalbe, I., Bornbusch, D., Gonnermann, M., Wojatschek, C., et al. (2005) · Oncology Research and Treatment · doi:10.1159/000084595 · Cited by 71
Jordinson, M., El‐Hariry, I. A., Calnan, D. P., et al. (1999) · Gut · doi:10.1136/gut.44.5.709 · Cited by 68
McLaughlin, P. M. J., Harmsen, M. C., Dokter, W. H. A., Kroesen, B., van der Molen, H., Brinker, M. G. L., Hollema, H., Ruiters, M. H. J., Buys, C. H. C. M., & de Leij, L. F. M. H. (2001) · PubMed · Cited by 67
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas
Bono, J. S. D., Tolcher, A. W., Forero-Torres, A., Vanhove, G. F. A., Takimoto, C. H. M., Bauer, R. J., Hammond, L. A., Patnaik, A., White, M., Shen, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0729 · Cited by 67
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., da Silva, A., Locher, M., Kischel, R., Lutterbüse, R., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0082-x · Cited by 61
Self-citationNeidhart, J. D., Allen, K. O., Barlow, D. L., Carpenter, M., Shaw, D. R., Triozzi, P. L., & Conry, R. M. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.08.021 · Cited by 55
Mosolits, S., Markovic, K., Frödin, J., Virving, L., Magnusson, C. G. M., Steinitz, M. O., Fagerberg, J., & Mellstedt, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0425 · Cited by 45
Ren‐Heidenreich, L., Davol, P. A., KOUTTAB, N. M., Elfenbein, G. J., & Lum, L. G. (2004) · Cancer · doi:10.1002/cncr.20060 · Cited by 34
Quak, J. J., van Dongen, G., Brakkee, J. G. P., Hayashida, D. J. S., Balm, A. J. M., Snow, G. B., & Meijer, C. J. L. M. (1990) · Hybridoma · doi:10.1089/hyb.1990.9.377 · Cited by 30
Oosterhoff, D., Overmeer, R. M., de Graaf, M., van der Meulen, I. H., Giaccone, G., van Beusechem, V. W., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602362 · Cited by 26
Cited by
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Self-citationNuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719
Self-citationEpCAM (CD326) finding its role in cancer
Baeuerle, P. A., & Gires, O. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603494 · Cited by 527
Self-citationModern isolation and separation techniques for extracellular vesicles
Liangsupree, T., Multia, E., & Riekkola, M.-L. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461773 · Cited by 512
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
Metadata
- Authors
- Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., Kononen, J., Simon, R., Sauter, G., & Baeuerle, P. A.
- Venue
- British Journal of Cancer
- Published
- 2006-01
- Volume
- 94
- Issue
- 1
- Pages
- 128-135
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1964743637
- Cited by
- 387
- References
- 39
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.